Press release
Psychosis in Parkinson's and Alzheimer's Disease Treatment Market Size, Forecast, Drugs, and Companies 2024
Psychosis in Parkinson's and Alzheimer's Disease Market
DelveInsight's "Psychosis in Parkinson's and Alzheimer's Disease Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Psychosis in Parkinson's and Alzheimer's Disease, historical and forecasted epidemiology as well as the Psychosis in Parkinson's and Alzheimer's Disease market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Unlock detailed insights into the Psychosis in Parkinson's and Alzheimer's Disease Market by downloading the comprehensive report from DelveInsight @ Psychosis in Parkinson's and Alzheimer's Disease Market- https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Psychosis in Parkinson's and Alzheimer's Disease Market Report
• As per DelveInsight analysis, it is estimated that the Psychosis in Parkinson's and Alzheimer's Disease treatment market will experience significant changes during the forecast period of 2024-2034, owing to the launch of new therapies that are in clinical development for its treatment and due to the increasing patient pool.
• As per DelveInsight analysis, in 2023, there were approximately 15.4 million diagnosed prevalent cases of Alzheimer's disease in the 7MM. Out of these, the US accounted for approximately 41% of the total cases, while, the EU4 and the UK accounted for the least with nearly 33% of the total, in 2023.
• As per DelveInsight analysis, there were approximately 6 million total diagnosed prevalent cases of psychosis in Alzheimer's disease, in the 7MM, in 2023. These cases are projected to increase during the forecast period (2024-2034).
• As per DelveInsight analysis, in 2023, the total diagnosed prevalent cases of Parkinson's Disease Psychosis in the 7MM were approximately 876 thousand cases. These cases are projected to increase during the forecast period (2024-2034).
• The leading Psychosis in Parkinson's and Alzheimer's Disease Companies such as ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
• Promising Psychosis in Parkinson's and Alzheimer's Disease Therapies such as NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
Gain a competitive edge in the Psychosis in Parkinson's and Alzheimer's Disease Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Psychosis in Parkinson's and Alzheimer's Disease Treatment Drugs- https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Psychosis in Parkinson's and Alzheimer's Disease Epidemiology Segmentation in the 7MM
• Psychosis in Parkinson's and Alzheimer's Disease Diagnosed Prevalent Cases
• Psychosis in Parkinson's and Alzheimer's Disease Gender-specific Cases
• Psychosis in Parkinson's and Alzheimer's Disease Age-specific Cases
Psychosis in Parkinson's and Alzheimer's Disease Treatment Market
The current treatment regime involves nonpharmacological and pharmacological approaches. The primary aim of the treatment is to reduce the frequency and severity of psychotic symptoms with minimal worsening of motor symptoms. The use of typical and atypical antipsychotics are the first-line treatment (e.g., aripiprazole, clozapine, quetiapine, etc.). However, atypical antipsychotics are often considered in the initial therapy, which reduces the risk of later deterioration in patients. Apart from antipsychotics, 5-HT3 receptor antagonists, acetylcholinesterase inhibitors (donepezil, rivastigmine), or other antidepressants are also used.
Discover key developments and opportunities in the Psychosis in Parkinson's and Alzheimer's Disease Market. Click here to learn more from DelveInsight's latest report @ Psychosis in Parkinson's and Alzheimer's Disease Market Size- https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Psychosis in Parkinson's and Alzheimer's Disease Market Insights
Psychosis is also common in most people with Alzheimer's disease throughout their illness. According to studies, over half of the people with Alzheimer's disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.
Psychosis in Parkinson's and Alzheimer's Disease Marketed Drugs
• NUPLAZID (pimavanserin): Acadia Pharmaceuticals
Psychosis in Parkinson's and Alzheimer's Disease Emerging Drugs
• Ulotaront (SEP-363856): Sunovion Pharmaceuticals
• KarXT (xanomeline-trospium): Karuna Therapeutics
• ITI-1284: Intra-Cellular Therapies
Psychosis in Parkinson's and Alzheimer's Disease Market Outlook
Psychosis is also common in most people with Alzheimer's disease throughout their illness. According to studies, over half of the people with Alzheimer's disease will experience psychotic symptoms during their illness. Antipsychotic medications are the gold-standard treatment for psychotic episodes and disorders, and the choice, dosing, and administration of the medication largely depend on the scenario. Along with medications, family and caregivers also play an important role in managing psychosis, including providing a safe and therapeutic environment. Along with medications, cognitive behavioral therapy is integral in treating patients with psychotic symptoms and is usually recommended as the initial treatment regime.
Download DelveInsight's Psychosis in Parkinson's and Alzheimer's Disease Market report today and stay ahead in this rapidly evolving field. @ Psychosis in Parkinson's and Alzheimer's Disease Clinical Trials- https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Psychosis in Parkinson's and Alzheimer's Disease Market Report
• Coverage- 7MM
• Psychosis in Parkinson's and Alzheimer's Disease Companies- ACADIA Pharmaceuticals, Biogen, Roche, Genentech, Lundbeck, Novartis, Pfizer, Janssen Pharmaceuticals (a subsidiary of Johnson & Johnson), Eli Lilly and Company, AstraZeneca, Otsuka Pharmaceutical, Eisai Co., Ltd., Neurocrine Biosciences, Teva Pharmaceuticals, UCB, Sumitomo Dainippon Pharma, Sunovion Pharmaceuticals, Mitsubishi Tanabe Pharma, Takeda Pharmaceutical Company, Merck & Co., Boehringer Ingelheim, and others.
• Psychosis in Parkinson's and Alzheimer's Disease Therapies- NUPLAZID (pimavanserin), Ulotaront (SEP-363856), KarXT (xanomeline-trospium), ITI-1284, and others.
• Psychosis in Parkinson's and Alzheimer's Disease Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Psychosis in Parkinson's and Alzheimer's Disease Unmet Needs, KOL's views, Analyst's views, Psychosis in Parkinson's and Alzheimer's Disease Market Access and Reimbursement
Download the report to understand which factors are driving Psychosis in Parkinson's and Alzheimer's Disease Market Trends @ Psychosis in Parkinson's and Alzheimer's Disease Market Trends- https://www.delveinsight.com/sample-request/psychosis-in-parkinsons-and-alzheimers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Key Insights
2. Report Introduction
3. Psychosis in PD and AD Market Overview at a Glance
4. Methodology of Psychosis in Parkinson's disease and Alzheimer's disease Epidemiology and Market
5. Executive Summary of Psychosis in Parkinson's disease and Alzheimer's disease
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
10. Marketed Drugs
11. Emerging Drugs
12. Psychosis in Parkinson's disease and Alzheimer's disease: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight
List of Top Selling Market Research Reports in 2024
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
pigment epithelial detachment market- https://www.delveinsight.com/report-store/pigment-epithelial-detachment-market
Neuroendocrine Tumor Market- https://www.delveinsight.com/report-store/neuroendocrine-tumors-net-market
medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market-insight
antibody drug conjugate market- https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
keloid market- https://www.delveinsight.com/report-store/keloid-market
mouth neoplasms market- https://www.delveinsight.com/report-store/mouth-neoplasms-market
urinary retention market- https://www.delveinsight.com/report-store/urinary-retention-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
spinal implants market- https://www.delveinsight.com/report-store/spinal-implants-market
transcatheter heart valve replacement devices market- https://www.delveinsight.com/report-store/transcatheter-heart-valve-replacement-devices-market
urea cycle disorders market- https://www.delveinsight.com/report-store/urea-cycle-disorders-market
intraocular lens market- https://www.delveinsight.com/report-store/intraocular-lens-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
vascular grafts market- https://www.delveinsight.com/report-store/vascular-grafts-market
embolotherapy market- https://www.delveinsight.com/report-store/embolotherapy-market
skin neoplasm market- https://www.delveinsight.com/report-store/skin-neoplasms-market
pelvic organ prolapse market- https://www.delveinsight.com/report-store/pelvic-organ-prolapse-market
thrombectomy devices market- https://www.delveinsight.com/report-store/thrombectomy-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
myeloproliferative neoplasms market- https://www.delveinsight.com/report-store/myeloproliferative-neoplasms-market
brucellosis market- https://www.delveinsight.com/report-store/brucellosis-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
endoscopic ultrasound market- https://www.delveinsight.com/report-store/endoscopic-ultrasound-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
wilms tumor market- https://www.delveinsight.com/report-store/wilms-tumor-market
rhabdomyosarcoma market- https://www.delveinsight.com/report-store/rhabdomyosarcoma-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Psychosis in Parkinson's and Alzheimer's Disease Treatment Market Size, Forecast, Drugs, and Companies 2024 here
News-ID: 3687206 • Views: …
More Releases from DelveInsight Business Research LLP
Infantile Spasms Treatment Market Size, Forecast, Drugs, and Companies 2024
Infantile Spasms Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Infantile Spasms Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Infantile Spasms Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Infantile Spasms, historical and…
Leptomeningeal Metastases Treatment Market Size, Forecast, Drugs, and Companies …
Leptomeningeal Metastases Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Leptomeningeal Metastases Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and…
HDAC Inhibitor Pipeline Therapeutics, Assessment, Companies, Products, Unmet Nee …
DelveInsight's, "HDAC Inhibitor Pipeline Insight 2024" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HDAC Inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our comprehensive HDAC Inhibitor Pipeline Report to stay informed…
Retinitis Pigmentosa Pipeline Therapeutics, Assessment, Companies, Products, Unm …
DelveInsight's, "Retinitis Pigmentosa Pipeline Insight 2024" report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Retinitis Pigmentosa pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our comprehensive Retinitis Pigmentosa Pipeline Report to stay informed…
More Releases for Alzheimer
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
Anti-β-Alzheimer Therapies Market : Consumption, Revenue, Applications With Maj …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer…
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
About Alzheimer Diagnostic Tests Market
GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage.
The report provides comprehensive information on the pipeline products with comparative analysis of…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
